Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a form of liver cancer that commonly arises in patients with chronic liver disease. Patients who present with early-stage disease, even after curative intent resection or ablation, are likely to develop local recurrence or metastatic disease. Chronic inflammation disrupts the tightly relegated immune system of the liver, making it more susceptible to carcinogenesis. In turn, research has focused on leveraging immunotherapy for these patients. This approach has primarily been accomplished through immune checkpoint inhibitors, which are monoclonal antibodies that inhibit immune checkpoints and restore T cells’ activity against cancer cells. The IMbrave150 and HIMALAYA trials established immunotherapy as the first-line treatment for patients with advanced HCC. Therefore, there has been interest in expanding the indications for immunotherapy among patients with HCC to the neoadjuvant and adjuvant settings. Furthermore, locoregional therapies, like radiation therapy, may be able to prime the tumor microenvironment and make it more susceptible to immunotherapy, thereby improving response to treatment. We herein review recent research and clinical trials focused on the use of immunotherapy in the neoadjuvant and adjuvant setting for patients with HCC.

Keywords

Surgery / hepatocellular carcinoma / immunotherapy / radiation therapy / neoadjuvant therapy

References

[1] Robinson MW,O'Farrelly C.Liver immunology and its role in inflammation and homeostasis.Cell Mol Immunol2016;13:267-76 PMCID:PMC4856809

[2] He X.Immune checkpoint signaling and cancer immunotherapy.Cell Res2020;30:660-9 PMCID:PMC7395714

[3] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[4] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[5] Abou-Alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid2022;1:EVIDoa2100070.

[6] Llovet JM,Kulik L.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2021;18:293-313

[7] NCCN: hepatocellular carcinoma. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf [Last accessed on 26 Apr 2024]

[8] Abdalla EK,Hasegawa K.Treatment of large and advanced hepatocellular carcinoma.Ann Surg Oncol2008;15:979-85

[9] Truty MJ.Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique.Ann Surg Oncol2010;17:1219-25 PMCID:PMC4103783

[10] Vauthey JN,Esnaola NF.Simplified staging for hepatocellular carcinoma.J Clin Oncol2002;20:1527-36

[11] Kokudo N,Hasegawa K.Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019 update.Hepatol Res2019;49:1109-13

[12] Franzin R,Spadaccino F.The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?.Front Immunol2020;11:574271 PMCID:PMC7580288

[13] Gao Y,Yang C.Overcoming T cell exhaustion via immune checkpoint modulation with a dendrimer-based hybrid nanocomplex.Adv Healthc Mater2021;10:e2100833

[14] Lisovska N.Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: history, present issues and future development.Oncol Lett2022;23:190 PMCID:PMC9073577

[15] Ganesh K,Cercek A.Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol2019;16:361-75 PMCID:PMC7295073

[16] Rotte A.Combination of CTLA-4 and PD-1 blockers for treatment of cancer.J Exp Clin Cancer Res2019;38:255 PMCID:PMC6567914

[17] Wu Y,Huang A,Liu Y.CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.J Exp Med1997;185:1327-35 PMCID:PMC2196265

[18] Onuma AE,Huang H,Noonan A.Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment.Gene Expr2020;20:53-65 PMCID:PMC7284108

[19] Kassel R,Iezzoni JC,Pruett TL.Chronically inflamed livers up-regulate expression of inhibitory B7 family members.Hepatology2009;50:1625-37 PMCID:PMC2897253

[20] Wang BJ,Wang JZ.Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.World J Gastroenterol2011;17:3322-9 PMCID:PMC3160536

[21] Kaseb AO,Cao HST.Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.Lancet Gastroenterol Hepatol2022;7:208-18 PMCID:PMC8840977

[22] D'alessio A,Spalding D.Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: the PRIME-HCC trial.JCO2022;40:4093

[23] Marron TU,Hamon P.Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.Lancet Gastroenterol Hepatol2022;7:219-29 PMCID:PMC9901534

[24] Xia Y,Qian X.Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.J Immunother Cancer2022;10:e004656 PMCID:PMC8981365

[25] Zhang B,Cui K.Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients.BMC Cancer2023;23:465 PMCID:PMC10199571

[26] Tomonari T,Sato Y.Clinical features and outcomes of conversion therapy in patients with unresectable hepatocellular carcinoma.Cancers (Basel)2023;15:5221 PMCID:PMC10650115

[27] Zhu XD,Shen YH.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 ANTIBODY COMbinations.Liver Cancer2021;10:320-9 PMCID:PMC8339461

[28] Zhang W,Han J.Surgery after conversion therapy with PD-1 Inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients.Front Oncol2021;11:747950 PMCID:PMC8560793

[29] Ho WJ,Durham J.Neoadjuvant cabozantinib and nivolumab convert locally advanced HCC into resectable disease with enhanced antitumor immunity.Nat Cancer2021;2:891-903 PMCID:PMC8594857

[30] Xu XF,Han J.Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China.JAMA Surg2019;154:209-17 PMCID:PMC6439634

[31] Hack SP,Chen M.IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Future Oncol2020;16:975-89

[32] Chow P,Cheng A.Abstract CT003: IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.Cancer Res2023;83:CT003

[33] Hiroishi K,Baba T.Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.J Gastroenterol2010;45:451-8

[34] Nobuoka D,Shirakawa H.Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.Int J Oncol2012;40:63-70

[35] Hansler J,Schuppan D.Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases.World J Gastroenterol2006;12:3716-21 PMCID:PMC4087464

[36] Ayaru L,Alisa A.Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.J Immunol2007;178:1914-22

[37] Rapoport BL.Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy.Int J Mol Sci2019;20:959 PMCID:PMC6412296

[38] Basu S,Suto R,Srivastava PK.Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.Int Immunol2000;12:1539-46

[39] Roberts EW,Binnewies M.Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma.Cancer Cell2016;30:324-36 PMCID:PMC5374862

[40] Xie L.Immunomodulatory effect of locoregional therapy in the tumor microenvironment.Mol Ther2023;31:951-69 PMCID:PMC10124087

[41] Duffy AG,Makorova-Rusher O.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol2017;66:545-51 PMCID:PMC5316490

[42] Guo C,Huang X.Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: a phase II trial.Hepatol Commun2023;7:e0054 PMCID:PMC9916103

[43] Wu JY,Li YN.Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: a multicenter retrospective study.Front Oncol2022;12:985380 PMCID:PMC9534527